Product Differentiation Gryphus Diagnostics offers BVBLUE, the only CLIA waived rapid sialidase test for bacterial vaginosis, highlighting a unique position in the diagnostic market with potential for expansion in point-of-care testing segments.

Market Expansion With over 7 million tests sold worldwide and a focus on expanding both domestically and internationally, there are significant growth opportunities by targeting healthcare providers and distributors seeking innovative diagnostic solutions.

Technological Presence Utilizing a modern tech stack including WordPress, Bootstrap, and SEO tools, Gryphus maintains an accessible online platform, facilitating outreach to global partners and increasing sales channels.

Financial Opportunity Operating within a revenue range of 1 to 10 million dollars and serving a niche market, Gryphus presents a compelling sales opportunity for distributors and partners looking to add a reliable, high-demand diagnostic product.

Industry Positioning As a specialized biotech manufacturer with a focused product line, Gryphus can benefit from partnerships within large healthcare companies and laboratories to accelerate market penetration and capitalize on current trends toward rapid diagnostics.